The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Will Be The Estimated Market Valuation Of The Osimertinib Drugs Market By The End Of 2030?
The osimertinib drugs market has experienced rapid expansion in its size recently. This market is projected to expand from $7.75 billion in 2025 to $8.94 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.3%. Historically, this growth can be attributed to several factors including an increased incidence of nsclc, more widespread egfr mutation testing, its clinical success compared to first-generation tkis, numerous regulatory approvals across key markets, and an overall rise in oncology healthcare spending.
The osimertinib drugs market size is anticipated to undergo rapid expansion over the next few years. It is projected to achieve $16.25 billion by 2030, growing at a compound annual growth rate (CAGR) of 16.1%. This growth during the forecast period can be ascribed to the broadening of precision oncology programs, increasing diagnosis rates in developing economies, the advancement of next-generation EGFR inhibitors, wider reimbursement coverage, and ongoing clinical trials for new indications. Significant trends observed in the forecast period include its expanded application as a first-line EGFR therapy, rising adoption in the treatment of metastatic NSCLC, a growing preference for oral targeted therapies, increasing research into combination therapies, and improved patient compliance through once-daily dosing.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13255&type=smp
What Major Growth Drivers Are Shaping The Outlook Of The Osimertinib Drugs Market?
The rising occurrence of lung cancer is anticipated to boost the expansion of the osimertinib drug market. This condition is a malignancy that develops in lung tissues, primarily affecting the cells lining the air passages. Osimertinib serves as a treatment for lung cancer, functioning by inhibiting particular proteins crucial for the proliferation and metastasis of cancer cells. For example, data from January 2023 by the American Cancer Society Facts and Figures, a US-based professional organization, indicated that new lung and bronchus cancer diagnoses were estimated at 236,740 in 2022 and 238,340 in 2023, with estimated deaths at 130,180 in 2022 and 127,070 in 2023. Consequently, the rising prevalence of lung cancer is propelling the demand for the osimertinib drug market.
Which Segment Classifications Shape The Osimertinib Drugs Market?
The osimertinib drugs market covered in this report is segmented –
1) By Type: 40 mg, 80 mg
2) By Distribution Channel: Hospital Pharmacy, Drug Store And Retail Pharmacy, Online Pharmacy
3) By Application: Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Other Applications
Subsegments:
1) By 40 mg: Maintenance Therapy in Tolerability-Sensitive Patients, Dose Adjustment for Drug–Drug Interactions
2) By 80 mg: First-Line Treatment for EGFR-Mutated NSCLC, Second-Line Treatment for T790M-Positive NSCLC
How Are Trends Impacting The Osimertinib Drugs Market?
Leading companies within the osimertinib drugs market are concentrating on targeted therapies to enhance patient outcomes in non-small cell lung cancer (NSCLC), particularly for individuals with EGFR mutations, striving to improve treatment efficacy and the overall quality of life for patients. These firms are also dedicating resources to clinical trials and research partnerships to broaden osimertinib’s approved uses and to investigate its effectiveness in conjunction with other therapies for more extensive patient advantages. For example, in September 2024, AstraZeneca Pharmaceuticals LP, a US-based pharmaceutical company, introduced osimertinib (Tagrisso) for adults diagnosed with locally advanced, unresectable non-small cell lung cancer (NSCLC) exhibiting specific EGFR mutations, having received approval from the FDA. This regulatory clearance came after a clinical trial showcased notable improvements in progression-free survival when compared to a placebo.
Which Companies Are Expanding Their Footprint In The Osimertinib Drugs Market?
Major companies operating in the osimertinib drugs market are AstraZeneca plc, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Zydus Lifesciences Limited, Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Aristo Pharmaceuticals Private Limited, Incepta Pharmaceuticals Ltd., Beacon Pharmaceutical Limited, Drug International Limited, MSN Laboratories Pvt Ltd., Hetero Drugs Ltd., Accord Healthcare Limited, Dolphin Pharmaceutical Limited, Radiant Pharmaceuticals Ltd., Beximco Pharmaceuticals Ltd., Eskayef Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Natco Pharma Limited, Alkem Laboratories Ltd.
Read the full osimertinib drugs market report here:
https://www.thebusinessresearchcompany.com/report/osimertinib-drugs-global-market-report
Which Regions Are Projected To Dominate The Osimertinib Drugs Market In The Coming Years?
North America was the largest region in the osimertinib drugs market in 2025. The regions covered in the osimertinib drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Osimertinib Drugs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=13255&type=smp
Browse Through More Reports Similar to the Global Osimertinib Drugs Market 2026, By The Business Research Company
Osimertinib Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/osimertinib-drugs-global-market-report
Osteoporosis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/osteoporosis-drugs-global-market-report
Alexipharmic Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/alexipharmic-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model